These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 9524798

  • 1. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto MR, Gianotti L, Ghigo E, Chiumello G.
    Dement Geriatr Cogn Disord; 1998; 9(2):78-81. PubMed ID: 9524798
    [Abstract] [Full Text] [Related]

  • 2. The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome.
    Arvat E, Gianotti L, Ragusa L, Valetto MR, Cappa M, Aimaretti G, Ramunni J, Grottoli S, Camanni F, Ghigo E.
    Dementia; 1996; 7(5):288-92. PubMed ID: 8872421
    [Abstract] [Full Text] [Related]

  • 3. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M, Maccario M, Savio P, Valetto MR, Aimaretti G, Grottoli S, Oleandri SE, Baffoni C, Tassone F, Arvat E, Camanni F, Ghigo E.
    Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
    [Abstract] [Full Text] [Related]

  • 4. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E.
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [Abstract] [Full Text] [Related]

  • 5. Effect of testosterone replacement therapy on the somatotrope responsiveness to GHRH alone or combined with pyridostigmine and on sympathoadrenal activity in patients with hypogonadism.
    Del Rio G, Carani C, Velardo A, Zizzo G, Procopio M, Coletta F, Marrama P, Ghigo E.
    J Endocrinol Invest; 1995 Oct; 18(9):690-5. PubMed ID: 8719299
    [Abstract] [Full Text] [Related]

  • 6. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M, Maccario M, Savio P, Valetto MR, Aimaretti G, Grottoli S, Oleandri SE, Baffoni C, Tassone F, Arvat E, Camanni F, Ghigo E.
    Minerva Endocrinol; 1999 Oct; 24(3-4):107-11. PubMed ID: 10953725
    [Abstract] [Full Text] [Related]

  • 7. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
    Grottoli S, Razzore P, Arvat E, Oleandri SE, Rossetto R, Ciccarelli E, Camanni F, Ghigo E.
    J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917
    [Abstract] [Full Text] [Related]

  • 8. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging.
    Arvat E, Ceda GP, Di Vito L, Ramunni J, Gianotti L, Broglio F, Deghenghi R, Ghigo E.
    Pituitary; 1998 Apr; 1(1):51-8. PubMed ID: 11081183
    [Abstract] [Full Text] [Related]

  • 9. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R, Valente F, Dieguez C, Zini M, Procopio M, Portioli I, Ghigo E.
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [Abstract] [Full Text] [Related]

  • 10. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.
    Grottoli S, Procopio M, Maccario M, Zini M, Oleandri SE, Tassone F, Valcavi R, Ghigo E.
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2261-5. PubMed ID: 9215304
    [Abstract] [Full Text] [Related]

  • 11. GH secretion in Prader-Labhard-Willi syndrome: somatotrope responsiveness to GHRH is enhanced by arginine but not by pyridostigmine.
    Beccaria L, Bosio L, Sanzari A, Aimaretti G, Ghigo E, Chiumello G.
    J Pediatr Endocrinol Metab; 1996 Jul; 9(6):577-83. PubMed ID: 9004172
    [Abstract] [Full Text] [Related]

  • 12. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [Abstract] [Full Text] [Related]

  • 13. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, Ghigo MC, Camanni F.
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [Abstract] [Full Text] [Related]

  • 14. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.
    Bellone J, Bartolotta E, Sgattoni C, Aimaretti G, Arvat E, Bellone S, Deghenghi R, Ghigo E.
    J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989
    [Abstract] [Full Text] [Related]

  • 15. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G, Grugni G, Morabito F.
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [Abstract] [Full Text] [Related]

  • 16. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.
    Ghigo E, Imperiale E, Boffano GM, Mazza E, Bellone J, Arvat E, Procopio M, Goffi S, Barreca A, Chiabotto P.
    J Endocrinol Invest; 1990 Apr; 13(4):307-16. PubMed ID: 2115060
    [Abstract] [Full Text] [Related]

  • 17. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS, Scanlon MF, Peters JR.
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
    [Abstract] [Full Text] [Related]

  • 18. Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects.
    Ghigo E, Ceda GP, Valcavi R, Goffi S, Zini M, Mucci M, Valenti G, Cocchi D, Müller EE, Camanni F.
    J Endocrinol Invest; 1994 Feb; 17(2):113-7. PubMed ID: 8006330
    [Abstract] [Full Text] [Related]

  • 19. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women.
    Arvat E, Cappa M, Casanueva FF, Dieguez C, Ghigo E, Nicolosi M, Valcavi R, Zini M.
    J Clin Endocrinol Metab; 1993 Feb; 76(2):374-7. PubMed ID: 8432781
    [Abstract] [Full Text] [Related]

  • 20. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging.
    Ghigo E, Goffi S, Arvat E, Nicolosi M, Procopio M, Bellone J, Imperiale E, Mazza E, Baracchi G, Camanni F.
    Acta Endocrinol (Copenh); 1990 Aug; 123(2):169-73. PubMed ID: 2220258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.